RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 11..20 of 1947 - per page Previous page Next page
Order by
An anti-mesothelin antibody of human origin has been generated; it has the ability to efficiently recognize mesothelin on the surface of cells, and induce ADCC in mesothelin-positive cells. More
Rotavirus is a major cause of diarrhea in infants and young children throughout the world. WHO has declared that the development of an anti-rotavirus vaccine is a project of the highest priority. More
The technology provides methods for diagnosis and treatment of conditions such as cancer, diabetes, or other conditions that are influenced by AM levels. More
Two anti-CD22 antibodies of human origin have been generated; each has the ability to recognize CD22 on the surface of Raji cells. More
This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. More
Plk1 ELISA assay using peptide substrates that are specific for Plk1 More
The present invention provides assays for the detection of human RFX4_v3 polymorphisms or deficiencies that may lead to the determination of an individual's risk of developing hydrocephalus. More
Novel anti-HIV human monoclonal antibody exhibits a unique binding activity compared to its counterparts. More
MGD3 monoclonal antibody binds human Dectin-1 with high affinity and regulates production of cytokines TNF-α and Interleukin-10. MGD3 has a potential therapeutic use on inflammatory diseases. More
New monoclonal antibodies against megakaryocyte potentiation factor More
Displaying 11..20 of 1947 - per page Previous page Next page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Nov 2011 - 50 pages - $3,800
May 2011 - 102 pages - $3,835
Feb 2012 - 1350 pages - $2,695
Oct 2009 - 30 pages - $995
Dec 2011 - 45 pages - $1,900
Oct 2009 - 141 pages - $3,835

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us